IRD Stock Analysis: Buy, Sell, or Hold?
IRD - Opus Genetics, Inc. Common Stock
$4.55
-0.14 (-2.99%)
▼
5d:
+0.66%
30d:
-0.44%
90d:
+126.37%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When IRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IRD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IRD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IRD is currently trading at $4.55, which is considered fair relative to its 30-day fair value range of $4.04 to $4.93.
Technical Outlook: Technically, IRD is in a strong uptrend. Immediate support is located at $4.25, while resistance sits at $4.96.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.54 (+103.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRD is in a strong uptrend. Immediate support is located at $4.25, while resistance sits at $4.96.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.54 (+103.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$4.04 -
$4.93
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 103.4% below Wall St target ($9.54)
Fair Price Analysis
30-Day Fair Range
$4.04 -
$4.93
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$4.25
Resistance Level
$4.96
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.60
Wall Street Target
$9.54
(+103.4%)
Revenue Growth (YoY)
-10.2%
Share & Embed Analysis
Last updated: April 02, 2026 4:06 PM ET
Data refreshes hourly during market hours. Next update: 5:06 PM
Data refreshes hourly during market hours. Next update: 5:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashwath Jayagopal
SELL
3719 shares
2026-03-16
George Magrath
SELL
24438 shares
2026-03-16
Joseph K Schachle
SELL
3719 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |